Showing results (211-220 of 407) with videos related to

Sort By:
Pageof 41
Advances in Therapy|August 28, 2025
Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel DiseaseGerd R Burmester, Atul Deodhar, Alan D Irvine, et al.
Arthritis Research & Therapy|June 21, 2018
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritisVibeke Strand, Laure Gossec, Clare W J Proudfoot, et al.
Lancet (London, England)|January 9, 2013
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trialGerd R Burmester, Ricardo Blanco, Christina Charles-Schoeman, et al.
Rheumatology (Oxford, England)|November 17, 2020
Peripheral blood mononuclear cells are hypomethylated in active rheumatoid arthritis and methylation correlates with disease activityIlka Liebold, Andreas Grützkau, Anika Göckeritz, et al.
Arthritis Research & Therapy|August 14, 2015
Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritisLuisa Lindenberg, Lydia Spengler, Holger Bang, et al.
Annals of the Rheumatic Diseases|May 23, 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 yearsGerd R Burmester, Jacques-Eric Gottenberg, Roberto Caporali, et al.
The Journal of Rheumatology|April 3, 2018
Simultaneous Response in Several Domains in Patients with Psoriatic Disease Treated with Etanercept as Monotherapy or in Combination with Conventional Synthetic Disease-modifying Antirheumatic DrugsFrank Behrens, Lothar Meier, Jörg C Prinz, et al.
RMD Open|September 21, 2018
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitorsPeter Nash, Frank Behrens, Ana-Maria Orbai, et al.
Scientific Reports|March 22, 2025
Mechanical forces trigger invasive behavior in synovial fibroblasts through N-cadherin/ADAM15 -dependent modulation of LncRNA H19Tomasz Janczi, Beate Böhm, Yuliya Fehrl, et al.
Annals of the Rheumatic Diseases|June 14, 2020
Bacterial citrullinated epitopes generated by Porphyromonas gingivalis infection-a missing link for ACPA productionMadeleine Jenning, Bianka Marklein, Jimmy Ytterberg, et al.
Pageof 41